Patents Examined by Elizabeth Kemmerer
  • Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
    Patent number: 7063954
    Abstract: Screening methods for identifying compounds that bind to or activate corticotropin releasing factor2 receptors (CRF2R) and regulate or potentially regulate skeletal muscle mass or function in vivo are disclosed. Also disclosed are screening methods for identifying compounds that prolong or augment the activation of CRF2Rs or of CRF2R signal transduction pathways, increase CRF2R or increase CRF expression are provided. Pharmaceutical compositions comprising CRF2R agonists, antibodies to CRF2R and methods for increasing skeletal muscle mass or function or for the treatment of skeletal muscle atrophy using CRF2R as the target for intervention and methods for treatment of muscular dystrophies are described.
    Type: Grant
    Filed: August 27, 2003
    Date of Patent: June 20, 2006
    Assignee: The Procter & Gamble Company
    Inventors: Robert Joseph Isfort, Russell James Sheldon
  • Methods for screening GABA-modulatory compounds for specified pharmacological activities
    Patent number: 7060451
    Abstract: Methods are provided that are useful in assaying compounds for cognitive enhancing properties, anxiolytic properties, hypnotic properties, or antidepressant properties. These methods involve determining the in vitro efficacy and EC50 of the compounds at defined series of cloned GABAA subtype receptors composed of specific variants of ?, ?, and ? subunits in order to develop and an activity profile for each compound. Optionally, the binding affinities of the compounds at GABAA receptors are also determined. As an additional step the in vivo effects of the compounds may be tested in animal models.
    Type: Grant
    Filed: November 9, 2001
    Date of Patent: June 13, 2006
    Assignee: Neurogen Corporation
    Inventors: John Tallman, Dorothy Gallager, Kenneth Shaw, Geoffrey White, Marci Crandall, James Cassella, Lavanya Rajachandran, Pamela Albaugh
  • Antagonists of HMG1 for treating inflammatory conditions
    Patent number: 7060504
    Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
    Type: Grant
    Filed: September 11, 2002
    Date of Patent: June 13, 2006
    Assignee: North Shore-Long Island Jewish Research Institute
    Inventors: Kevin J. Tracey, Haichao Wang
  • Secreted and transmembrane polypeptides and nucleic acids encoding the same
    Patent number: 7056736
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: November 19, 2001
    Date of Patent: June 6, 2006
    Assignee: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Kevin P. Baker, David Botstein, Luc Desnoyers, Dan L. Eaton, Napoleone Ferrara, Sherman Fong, Hanspeter Gerber, Mary E. Gerritsen, Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, Ivar J. Kljavin, Mary A. Napier, James Pan, Nicholas F. Paoni, Margaret Ann Roy, Timothy A. Stewart, Daniel Tumas, Colin K. Watanabe, P. Mickey Williams, William I. Wood, Zemin Zhang
  • Receptor-type phosphotyrosine phosphatase-kappa antibodies
    Patent number: 7056508
    Abstract: A novel receptor-type protein tyrosine phosphatase-? (RPTP?) protein or glycoprotein and the DNA coding therefor is expressed in a wide variety of mammalian tissues. The RPTP? protein or glycoprotein may be produced by recombinant means. Antibodies to the protein, methods for measuring the quantity of the protein, methods for screening compounds, such as drugs, which can bind to the protein and inhibit or stimulate their enzymatic activity, are provided. Further, methods for inhibiting homophilic binding of Type II RPTP, especially RPTP? molecules are provided.
    Type: Grant
    Filed: October 1, 2001
    Date of Patent: June 6, 2006
    Assignees: New York University, Max Planck Gesellschaft Forgerung der Wissenschaften
    Inventors: Joseph Schlessinger, Jan M. Sap, Axel Ullrich, Wolfgang Vogel, Miriam Fuchs
  • 14273 Receptor, a novel G-protein coupled receptor
    Patent number: 7057028
    Abstract: The present invention relates to a newly identified receptor belonging to the superfamily of G-protein-coupled receptors. The invention also relates to polynucleotides encoding the receptor. The invention further relates to methods using the receptor polypeptides and polynucleotides as a target for diagnosis and treatment in receptor-mediated disorders, specifically, cardiovascular diseases, including congestive heart failure. The invention further relates to drug-screening methods using the receptor polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the receptor polypeptides and polynucleotides. The invention further relates to procedures for producing the receptor polypeptides and polynucleotides.
    Type: Grant
    Filed: February 13, 2002
    Date of Patent: June 6, 2006
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Maria Alexandra Glucksmann, Fong-Ying Tsai
  • Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
    Patent number: 7056882
    Abstract: The invention is a treatment for increasing the bone mass or preventing bone loss in an individual afflicted with a bone disease which includes administering to the individual a morphogen in a therapeutically effective amount so as to maintain or stimulate bone formation.
    Type: Grant
    Filed: September 13, 2001
    Date of Patent: June 6, 2006
    Assignee: Curis, Inc.
    Inventors: Thangavel Kuberasampath, Charles M. Cohen, Herrmann Oppermann, Engin Ozkaynak, David C. Rueger, John E. Smart, Roy H. L. Pang
  • DNA encoding peripheral-type benzodiazipine receptor associated protein 7 and applications or methods of use
    Patent number: 7056694
    Abstract: The present invention relates to nucleic acids encoding peripheral-type benzodiazepine receptor (PBR)-associated proteins (PAPs), and nucleic acids that hybridize or are variant of nucleic acids encoding the peripheral-type benzodiazepine receptor (PBR)-associated proteins (PAPs), which are capable of encoding proteins that regulate the function of PBRs affecting both steroid biosynthesis and mediating cholesterol delivery as well as other PBR-mediated functions.
    Type: Grant
    Filed: August 11, 1999
    Date of Patent: June 6, 2006
    Assignee: Georgetown University
    Inventors: Vassilios Papadopoulos, Hua Li
  • Polynucleotides encoding a novel glycine receptor alpha subunit expressed in the gastrointestinal tract, HGRA4, and splice variant thereof
    Patent number: 7056737
    Abstract: The present invention provides novel polynucleotides encoding HGRA4 polypeptides, fragments and homologues thereof. The present invention also provides novel polynucleotides encoding a HGRA4 splice variant, HGRA4sv. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGRA4 and HGRA4sv polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Grant
    Filed: February 13, 2002
    Date of Patent: June 6, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: John N. Feder, Liana Lee, Jian Chen, Nathan O. Siemers, Han Chang
  • Isolated human nuclear hormone receptors, nucleic acid molecules encoding human nuclear hormone receptors, and uses thereof
    Patent number: 7053045
    Abstract: The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the nuclear hormone receptor peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the nuclear hormone receptor peptides, and methods of identifying modulators of the nuclear hormone receptor peptides.
    Type: Grant
    Filed: May 4, 2004
    Date of Patent: May 30, 2006
    Assignee: Applera Corporation
    Inventors: Ming-Hui Wei, Jane Ye, Chunhua Yan, Karen A. Ketchum, Valentina Di Francesco, Ellen M. Beasley
  • Isolated islet beta-cell two-pore domain potassium channel
    Patent number: 7053180
    Abstract: The present invention provides polynucleotides encoding potassium channels as well as methods of using the potassium channels to treat and diagnose diabetes and a predisposition for diabetes.
    Type: Grant
    Filed: June 10, 2003
    Date of Patent: May 30, 2006
    Assignee: Metabolex, Inc.
    Inventors: Jeffrey D. Johnson, John F. Palma, Anthony C. Schweitzer, John E. Blume
  • Methods and reagents for tissue engineering of cartilage in vitro
    Patent number: 7052514
    Abstract: The present invention makes available an optimal concentration of a hedgehog polypeptide for modulating growth and/or cartilage production by chondrocytes. The present invention allows for improvements in the culturing of chondrocytes to develop cartilaginous tissue ex vivo suitable for implantation to replace damaged or deteriorated cartilage in a patient.
    Type: Grant
    Filed: April 27, 2001
    Date of Patent: May 30, 2006
    Assignee: Curis, Inc.
    Inventors: Karin Kellner, Kurt Lang, Apollon Papadimitriou, Ulrike Leser-Reiff, Michaela Schultz, Torsten Blunk, Achim Goepferich
  • Tumor necrosis related receptor, TR7
    Patent number: 7049422
    Abstract: TR7 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing TR7 polypeptides and polynucleotides in the design of protocols for the treatment of chronic and acute inflammation, arthritis, septicemia, autoimmune diseases (such as inflammatory bowel disease and psoriasis), transplant rejection, graft versus host disease, infection, stroke, ischemia, acute respiratory disease syndrome, restenosis, brain injury, AIDS, bone diseases, cancer (such as lymphoproliferative disorders), atherosclerosis, and Alzheimers disease, among others and diagnostic assays for such conditions.
    Type: Grant
    Filed: September 15, 2003
    Date of Patent: May 23, 2006
    Assignee: SmithKline Beecham Corporation
    Inventors: Keith Charles Deen, Mark R. Hurle, Peter Young, Kong B. Tan
  • Stimulation of hematopoiesis by ex vivo activated immune cells
    Patent number: 7048922
    Abstract: A protocol of activating and administering human blood cells so that bone marrow histology and/or blood cell counts of patients suffering from aplastic anemia approach normal. The protocol includes culturing the blood cells in the presence of a cytokine and an ionophore. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. 37 C.F.R. ยง 1.72(b).
    Type: Grant
    Filed: May 29, 2002
    Date of Patent: May 23, 2006
    Inventor: Demao Yang
  • KCNQ5, a novel potassium channel
    Patent number: 7049137
    Abstract: The invention provides isolated nucleic acid and amino acid sequences of KCNQ5, antibodies to KCNQ5, methods of detecting KCNQ5, methods of screening for potassium channel activators and inhibitors using biologically active KCNQ5, and kits for screening for activators and inhibitors of voltage-gated potassium channels comprising KCNQ5.
    Type: Grant
    Filed: March 15, 2001
    Date of Patent: May 23, 2006
    Assignee: Icagen, Inc.
    Inventor: Timothy J. Jegla
  • Epitope-tagged beta-amyloid precursor protein and DNA encoding the same
    Patent number: 7049138
    Abstract: The present invention is directed generally to methods and composition for monitoring the processing of epitope-tagged beta-APP. More specifically, the present invention relates to the use of such methods and composition for monitoring responses of cells expressing such epitope-tagged beta-APP or fragments thereof or cell free systems containing the epitope-tagged polypeptides to therapy of diseases associated with an altered metabolism of the beta amyloid precursor protein (APP), and for screening and evaluation of potential drugs for the treatment of these disorders, including Alzheimer's disease (AD).
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: May 23, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Dietmar A. Seiffert, Thomas J. Mitchell
  • Genes for Niemann-Pick type C disease
    Patent number: 7045675
    Abstract: A gene for type C Niemann-Pick disease (NP-C) is disclosed, along with the amino acid sequence of the encoded peptide. Applications which are made possible by the present invention include detection of NP-C carriers and diagnosis of NP-C sufferers. The murine ortholog of the human gene is also disclosed.
    Type: Grant
    Filed: July 29, 2002
    Date of Patent: May 16, 2006
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Eugene D Carstea, Danilo A. Tagle, Jill A. Morris, Peter G. Pentchev, William J. Pavan, Melissa A. Ashlock, Stacie K. Loftus, Jessie Gu
  • Endothelial-monocyte activating polypeptide III antibodies
    Patent number: 7045301
    Abstract: A human EMAP III polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for preventing and/or treating neoplasia. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention for detecting diseases, for example, cancer, are also disclosed.
    Type: Grant
    Filed: August 4, 2004
    Date of Patent: May 16, 2006
    Assignee: Human Genome Sciences, Inc.
    Inventors: Timothy A. Coleman, Craig A. Rosen
  • Methods of inhibiting or inducing bone formation
    Patent number: 7041645
    Abstract: The present invention relates to a pharmaceutical composition containing a mixture of stable folding variants of recombinant bone morphogenic proteins (rBMPs) and its use in therapy, especially in the treatment of orthopaedic and dental patients. Specifically, the present invention relates to a pharmaceutical composition containing a mixture of stable folding variants of at least two rBMPs or their monomers or mutants in a suitable carrier system.
    Type: Grant
    Filed: July 2, 2002
    Date of Patent: May 9, 2006
    Assignee: The University of Zurich
    Inventors: Hermann Sailer, Franz Weber
  • Nucleic acids encoding PRO1184 polypeptides
    Patent number: 7037679
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: November 19, 2001
    Date of Patent: May 2, 2006
    Assignee: Genentech, Inc.
    Inventors: Luc Desnoyers, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood